NCT02744222View on ClinicalTrials.gov

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

November 23, 2018

Study Completion Date

July 6, 2020

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIOLOGICAL

BCD-054 180 mcg

180 mcg intramuscularly once every two weeks

BIOLOGICAL

Avonex®

30 mcg intramuscularly once a week

BIOLOGICAL

BCD-054 240 mcg

240 mcg intramuscularly once every two weeks

OTHER

Placebo

intramuscularly once a week (0,5 ml)

Trial Locations (1)

Unknown

"State Budgetary Healthcare Institution of Nizhny Novgorod region Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY